CN1531423A - 具有均匀药物分布和效力的低剂量药物组合物的制备方法 - Google Patents
具有均匀药物分布和效力的低剂量药物组合物的制备方法 Download PDFInfo
- Publication number
- CN1531423A CN1531423A CNA028092554A CN02809255A CN1531423A CN 1531423 A CN1531423 A CN 1531423A CN A028092554 A CNA028092554 A CN A028092554A CN 02809255 A CN02809255 A CN 02809255A CN 1531423 A CN1531423 A CN 1531423A
- Authority
- CN
- China
- Prior art keywords
- phenyl
- active component
- fusion
- pyrrolidine
- cis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 50
- 238000002360 preparation method Methods 0.000 title claims description 32
- 230000000694 effects Effects 0.000 title claims description 12
- 238000009827 uniform distribution Methods 0.000 title description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 49
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 31
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 25
- 238000009513 drug distribution Methods 0.000 claims abstract description 6
- 230000004927 fusion Effects 0.000 claims description 57
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 30
- 239000002552 dosage form Substances 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 19
- 239000003085 diluting agent Substances 0.000 claims description 18
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims description 14
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000000651 prodrug Substances 0.000 claims description 12
- 229940002612 prodrug Drugs 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 238000009826 distribution Methods 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 239000000890 drug combination Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 16
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 239000007916 tablet composition Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 27
- 239000000243 solution Substances 0.000 description 22
- 229960002367 lasofoxifene Drugs 0.000 description 16
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 16
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000008101 lactose Substances 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- 229960001375 lactose Drugs 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 11
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000010410 layer Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000005550 wet granulation Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008119 colloidal silica Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- -1 lignose Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000001680 brushing effect Effects 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000007908 dry granulation Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- HJOOGTROABIIIU-UHFFFAOYSA-N 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine;hydrochloride Chemical compound Cl.C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 HJOOGTROABIIIU-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- FCLZCOCSZQNREK-UHFFFAOYSA-N Pyrrolidine, hydrochloride Chemical compound Cl.C1CCNC1 FCLZCOCSZQNREK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229910021485 fumed silica Inorganic materials 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000009492 tablet coating Methods 0.000 description 2
- 239000002700 tablet coating Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ONQBOTKLCMXPOF-UHFFFAOYSA-N 1-ethylpyrrolidine Chemical compound CCN1CCCC1 ONQBOTKLCMXPOF-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229950005953 camsilate Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VDCLSGXZVUDARN-UHFFFAOYSA-N molecular bromine;pyridine;hydrobromide Chemical compound Br.BrBr.C1=CC=NC=C1 VDCLSGXZVUDARN-UHFFFAOYSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 150000003377 silicon compounds Chemical class 0.000 description 1
- FDNAPBUWERUEDA-UHFFFAOYSA-N silicon tetrachloride Chemical compound Cl[Si](Cl)(Cl)Cl FDNAPBUWERUEDA-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明描述了具有均匀药物分布和效力的药物组合物的制备方法,该方法使用了二氧化硅以便在制备过程中减少活性组分的损耗。该方法特别用于制备低剂量片剂组合物。
Description
发明领域
本发明涉及具有均匀药物分布和效力的药物组合物的制备方法、涉及由此生产的组合物和药剂,本发明特别涉及用于制备低剂量片剂组合物的方法和组合物,所述的低剂量片剂组合物中含有二氧化硅以便减少制备过程中活性组分的损耗。
背景技术
US 5,552,412中描述了一类用于治疗或预防乳腺癌、骨质疏松、肥胖、心血管疾病、高胆固醇血症、子宫内膜异位症和前列腺疾病的有效和具有口服活性的选择性雌激素受体调节剂(SERMS)(例如四氢化萘-2-醇衍生物)。这些特定的SERMS因其在目前商购SERMS(例如雷洛昔芬)中改善的口服生物利用度而受到关注。US 5,552,412中所述的SERMS极为有效,由此使获得低剂量剂型。然而,低剂量范围的组合物制剂对维持药物产品生产过程中的持续效力和均匀性提出了挑战。特别关注活性组分因粘附或吸附在掺合步骤中活性SERM接触的金属表面(例如接触金属掺合机刀片和容器表面)上所造成的损耗。尽管可以有效实现手工擦刷步骤来回收粘附在小尺寸设备中的金属表面的活性组分,但是手工擦刷步骤在规模生产环境中既无效、也不理想。液体加工可以将药物产品生产过程中药物损耗问题减少到最低限度;然而,对氧化敏感的化合物(例如四氢化萘-2-醇衍生物)在不使活性组分发生降解情况下使得难以进行液体加工。因此,对将活性组分粘附在生产药剂、特别是那些具有低剂量含量药剂过程中活性组分粘附在金属表面上的情况减少到最低限度的改善的制剂和方法存在需求。
概要
本发明提供了具有均匀药物分布和效力的药物组合物的制备方法。该方法包括(下列顺序)下列步骤:(1)在高剪切成粒机中将二氧化硅和至少一种药物上可接受的赋形剂、载体或稀释剂掺合适当的时间(约5分钟)以产生掺合的混合物;(2)向成粒机中加入活性组分且再掺合一定时间期限(约10-15分钟)而形成活性掺合物;(3)将该活性掺合物从成粒机中转入掺合机中;(4)任选向所述的活性掺合物中加入一种或多种其它药物上可接受的赋形剂、载体或稀释剂;和(5)掺合适当时间期限(约5分钟)以形成具有均匀活性组分分布和均匀效力的药物组合物。然后将所得掺合的组合物进一步加工成所需单位剂型。在优选的剂型中,活性组分的含量为约0.01-10.0mg/单位剂量(优选约0.05-约5.0mg/单位剂量,更优选约0.05-约4.0mg/单位剂量,甚至更优选约0.1-约3.5mg/单位剂量,且最优选约0.1-2.5mg/单位剂量),而二氧化硅的含有量约占单位剂型重量的约0.1-2%(更优选占单位剂型重量的约0.15-约1.0%且最优选占单位剂型重量的约0.25-约0.75%)。
在本发明的另一个实施方案中,提供了使用上述方法制备的药物组合物。特别提供了低剂量药物组合物,该药物组合物包括活性组分(优选拉索昔芬)、二氧化硅和至少一种药物上可接受的赋形剂、载体或稀释剂,其中所述的活性组分的含量低于4.0%w/w活性组分(更优选≥约0.01%w/w活性组分和<4%w/w活性组分,甚至更优选≥约0.01%w/w活性组分和≤约3.5%w/w活性组分,最优选≥约0.1%w/w活性组分和≤约2.5%w/w活性组分)且二氧化硅的含量为约0.1-约2重量%。
在本发明的另一个实施方案中,提供了通过上述制成单位剂型、特别是低剂量剂型的方法制备的药剂。
定义
本文所用的术语"均匀分布"指的是满足10个独立的掺合物样品的FDA标准(工业 ANDA 指南(Guidance for Industry ANDA′s):掺合物均匀分析(Blend Uniformity Analysis),1999年8月公布)的掺合的混合物,所述样品达到90-110%理论强度的效力且就所有掺合样品而言RSD均<5%。
术语"均匀的效力"指的是将药物物质活性在整个生产过程中维持在大于或等于约90%的水平的掺合的混合物。
术语"药物上可接受的"指的是物质或组合物必须在化学和/或毒理学上与制剂中含有的其它组分和/或与用该制剂治疗的哺乳动物相容。
术语"活性组分"指的是有治疗活性的化合物及其任意前体药物和所述化合物和前体药物的药物上可接受的盐、水合物和溶剂合物。
术语"适当时间期限"或"适宜时间期限"指的是获得所需作用或结果所必需的时间期限。例如,可以将混合物掺合至使效力分布达到指定应用或应用掺合的混合物的可接受的定性范围。
本文所用的术语"单位剂量"指的是含有为产生所需治疗作用计算的活性组分预定量的物理形态上离散的单位。单位剂量可以是片剂、胶囊剂、小药囊等本文称作"单位剂型"的形式。
详细说明
本发明提供了用于维持含有高效活性组分的药物组合物生产过程中的均匀性和效力的方法。该方法包括使药物组合物或药剂生产过程中粘附在设备金属表面上的活性组分损耗减少到最低限度的措施。特别关注的活性组分是下列通式(I)的SERM化合物、其前体药物或所述化合物或所述前体药物的药物上可接受的盐、水合物或溶剂合物:
其中E和B独立地选自CH和N;R1是氢、羟基、氟或氯;且G是:
优选的化合物包括:顺式-6-(4-氟-苯基)-5-[4-(2-哌啶-1-基-乙氧基)-苯基]-5,6,7,8-四氢-萘-2-醇;(-)-顺式-6-苯基-5-[4-(2-吡咯烷-1-基-乙氧基)-苯基]-5,6,7,8-四氢-萘-2-醇;顺式-6-苯基-5-[4-(2-吡咯烷-1-基-乙氧基)-苯基]-5,6,7,8-四氢萘-2-醇;顺式-1-[6′-吡咯烷乙氧基-3′-吡啶基]-2-苯基-6-羟基-1,2,3,4-四氢萘-1-(4′-吡咯烷乙氧基苯基)-2-(4"-氟苯基)-6-羟基-1,2,3,4-四氢异喹啉;顺式-6-(4-羟基苯基)-5-[4-(2-哌啶-1-基-乙氧基)-苯基]-5,6,7,8-四氢萘-2-醇;和1-(4′-吡咯烷乙氧基苯基)-2-苯基-6-羟基-1,2,3,4-四氢异喹啉;更优选的化合物是顺式-6-苯基-5-[4-(2-吡咯烷-1-基乙氧基)苯基]-5,6,7,8-四氢萘-2-醇;其前体药物,或所述化合物或所述前体药物的药物上可接受的盐、水合物或溶剂合物。
通式(I)的化合物是极为有效的化合物,由此需要在生产过程中进行特定控制以减少操作者的接触。此外,通式(I)的化合物可能对氧化敏感,这种氧化可以限制或妨碍药物产品生产过程中含有过氧化物污染物的液体和材料(例如聚乙二醇)的应用。用于生产片剂的常规方法一般在压制成片剂前使用湿法或干法成粒步骤。
可以将用于干法成粒的混合方法类型分成广泛的两类型:(i)批量型;和(ii)连续型。制药工业中最普遍使用的类型是批量型,该方法可一次混合部分批量或总批量的制剂。在批量型混合器中,通过旋转混合器外壳或整体使颗粒运动。就不同类型批量型混合器的略图和描述而言,参见Pharmaceutical Dosage Forms,第2卷,Lieberman,H.A.,L.Lachman;和J.B.Schwartz(编辑),Marcel Dekker,Inc.,New York,pp 40-57(1990)。
在掺合/研磨/掺合干法成粒过程中,一般使用下列步骤:
(1)使活性组分通过适宜大小的筛且然后在掺合机(例如双壳掺合机)中掺合适当时间期限以产生掺合的混合物;
(2)通过适当大小的筛过滤赋形剂掺合物并将部分过滤的赋形剂掺合物加入到含有活性组分的掺合机中;
(3)将该混合物掺合适当时间期限;
(4)通过适当大小的筛过滤活性掺合物;
(5)给掺合机添加一半剩余过滤的赋形剂掺合物,随后添加来自步骤(4)的过滤的活性掺合物;
(6)将该混合物掺合适当时间期限;
(7)向活性组分混合物中加入剩余过滤的赋形剂掺合物并掺合适当时间期限;
(8)过滤来自通过研磨机的步骤(7)的掺合的混合物;
(9)将来自步骤(8)的活性组分混合物在掺合机中掺合适当时间期限;和
(10)加入任意其它的赋形剂、载体或稀释剂并掺合至获得可接受的物质分布为止。
常规的掺合/研磨/掺合干法存在几个缺陷。例如,劳动密集,粉尘操作增加了操作者接触活性组分的机会且与金属表面接触增加了效力损耗的风险。此外,因混合物具有宽颗粒大小分布且颗粒密度差异大而观察到了分离的问题。转鼓型掺合机一般并不适合于细颗粒系统,这是因为没有足够的减少颗粒团聚的剪切力,且如果粉末自由流动,那么可能因添加低剂量活性组分而需要连续稀释。
当将上述干成粒法用于掺合含有通式(I)化合物的制剂时,通过成粒的颗粒观察到了不均匀分布的效力。尽管操作者接触活性组分的可能性在常规湿法成粒观察中得到降低,但是在增加化合物氧化可能性的工艺过程中活性组分接触液体和溶解的氧。降低通式(I)化合物在湿法成粒中的化学不稳定性的尝试并未成功。然而,申请人发现应用适合用于干法的高剪切湿法掺合设备致力于操作者接触药物并因常规干法和湿法成粒过程中观察到的氧化活性组分降解减少的问题。
高速成粒机是带有大混合刮料机刀片的固定壳混合器,其中所述的大混合刮料机刀片在混合器容器中混合所述组分、消除死角并将混合器中的内含物传送至最终混合所述组分的高速切碎机刀片。该设备速度极快且提供了最终的固体/固体混合。在竖型混合器(例如商购自LODIGEIndustries,Paderborn,Germany;NIRO Inc.,Columbia,MD;和DIOSNADierks&SoehneGmbH,Osnabrueck,Germany的设备)中,旋转混合叶轮以离心方式高速混合颗粒,使物质产生高度流化的涡旋。以极高速度旋转的切碎机粉碎上升循环的物质并将产物转成垂直流动。关于更为详细的描述,参见Record,P.C.,Manuf.Chem.Aerosol.News,50,65(1979)。其它合适的高速成粒机包括SpectrumTM和Pharma MatrixTM(均商购自Niro Pharma Systems,Columbia,MD)。
本发明提供了包括下列步骤的干法:
(1)在高剪切成粒机中将二氧化硅和至少一种药物上可接受的赋形剂、载体或稀释剂掺合适当的时间;
(2)向成粒机中加入活性组分且再掺合一定时间期限而形成活性掺合物;
(3)将该活性掺合物从成粒机中转入掺合机中;
(4)任选向所述的混合物中加入一种或多种其它药物上可接受的赋形剂、载体或稀释剂;和
(5)掺合适当时间期限以便在组合物中形成具有均匀活性组分具有分布的药物组合物。
将最终的药物组合物加工成单位剂型(例如片剂、胶囊剂或小药囊)且然后包装用于分发。该加工步骤随特定的单位剂型而改变。例如,一般在压力下将片剂压制成所需形状且胶囊剂或小药囊使用简单的填充操作。本领域技术人员充分熟知用于生产不同单位剂型的方法。
活性掺合物一般包括一种或多种药物上可接受的赋形剂、载体或稀释剂。所用的具体载体、稀释剂或赋形剂取决于活性组分所应用的方式和目的。一般来说,片剂包括诸如稀释剂、粘合剂、润滑剂、崩解剂及其混合物这样的物质。合适的稀释剂包括各种类型的淀粉、乳糖、甘露糖醇、高岭土、磷酸钙或硫酸钙、无机盐(例如氯化钠)、糖粉和粉状纤维素衍生物。为了确保掺合物中内含物的均匀性,优选使用小于或等于约30微米体积平均直径的药物物质颗粒。优选的稀释剂是微晶纤维素(例如商购自FMCPharmaceutical,Philadelphia,PA的AvicelPH102或PH101)和乳糖。微晶纤维素的平均颗粒大小一般在约90μm-约200μm的范围。合适的乳糖等级包括无水乳糖(平均约152μm)、乳糖一水合物和喷雾干燥的乳糖(例如Fast FloTM乳糖,约87um的平均值,商购自Foremost Corp.,Baraboo,WI)。
如果需要,可以加入粘合剂。合适的粘合剂包括诸如纤维素(例如纤维素、甲基纤维素、乙基纤维素和羟甲基纤维素)、聚丙基吡咯烷酮、聚乙烯吡咯烷酮、明胶、阿拉伯树胶、聚乙二醇、淀粉、糖(例如乳糖、蔗糖、果糖和葡萄糖)、天然和合成树胶(例如阿拉伯胶、藻酸盐和阿拉伯树胶)和蜡这样的物质。
一般在片剂中使用润滑剂以防止片剂和冲头在冲模中粘着。合适的润滑剂包括滑润固体,诸如滑石、硬脂酸镁和硬脂酸钙、硬脂酸、无水轻质硅酸和氢化植物油。优选的润滑剂是硬脂酸镁。
还可以将崩解剂加入到组合物中以使剂型破碎并释放所述化合物。合适的崩解剂包括淀粉(例如玉米淀粉或马铃薯淀粉和羟丙基淀粉),粘土、纤维素(例如纤维素、木纤维素、甲基纤维素或乙基纤维素、低取代的羟丙基纤维素和羧甲基纤维素)、琼脂、藻胶(例如藻酸)、粉状天然海绵状物、阳离子交换树脂、柑橘属的果肉、膨润土、碳酸氢钠、磷酸钙、柠檬酸钙、十二烷基硫酸钠和树胶(例如瓜耳胶)。
其它有用的添加剂包括诸如延缓溶解剂(例如石蜡)、再吸收加速剂(例如季铵化合物)、表面活性剂(例如鲸蜡醇、硬脂酸甘油酯和十二烷基硫酸钠)、吸附载体(例如高岭土和膨润土)、防腐剂、增甜剂、着色剂、调味剂(例如柠檬酸、薄荷醇、甘氨酸或桔粉)、稳定剂(例如柠檬酸或柠檬酸钠)、粘合剂(例如羟丙基甲基纤维素)及其混合物这样的物质。
在将成分加入高剪切成粒机进行开始的掺合步骤的顺序上存在很大程度的灵活性。优选首先不将药物物质加入到高剪切筒体中。一般在高剪切成粒机中的掺合时间为约10分钟-约15分钟。尽管可以使用15分钟以上的掺合时间,但是应谨慎考虑以不使掺合物分层。成粒机叶轮的速度一般以约55%-约65%的单位能力运转且切碎机优选以最慢的速度设置运转。叶轮速度过快可以导致掺合物流化并使掺合效力损耗。
在高剪切掺合步骤后,在双壳"V"型或料箱掺合机中掺合活性掺合物。一般的掺合时间为约5分钟,不过,已经成功地将小批量掺合了高达约15分钟。然后向活性掺合物中加入润滑剂并在双壳"V"型或料箱掺合机中掺合约5分钟。
上述工艺产生了有效混合并使活性组分的分布更为均匀而不会使活性组分发生明显的降解;然而,因化合物与设备金属表面(例如刀片和容器表面)粘附或吸附而导致的活性组分损耗尤其对低剂量制剂(例如低于4mg/剂量单位)而言提出了另外的挑战。添加诸如滑石这样的助流剂不会解决该难题。尽管向制剂中添加滑石减少了掺合工艺中活性组分的损耗(掺合的组合物中的效力由77.2%增加到91.0%),但是滑石不会完全防止与金属表面的粘附。当在掺合滑石制剂后手工实施擦刷步骤时,观察到效力增加到96.8%,这表明约有5%-约6%的活性组分仍然粘附在金属表面上。诸如通式(I)化合物这样极为有效的活性组分有5-6%损耗是显著的。然而,当向制剂中加入二氧化硅(例如得自W.R.Grace,Columbia,MD的SyloidTM244FP)时,观察到不添加手工擦刷步骤而使掺合组合物的效力从77.2%增加到了96.3%。
尽管向药物制剂中添加二氧化硅用于改善粉末掺合物的流动性并将片重的变化减小到最低限度,但是混入SiO2(如上述所观察到的)出人意料和令人意外地减少了因活性组分与加工设备金属表面吸附或粘附所导致的损耗。各种二氧化硅商购自许多商品供应商且对本领域技术人员而言是众所周知的。特别有用的二氧化硅是胶态二氧化硅,它是通过对诸如四氯化硅这样的硅化合物进行汽相水解制备的亚微热解法二氧化硅。胶态二氧化硅是商购自包括Cabot Corporation,Boston,MA(Cab-O-SilTM)、Degussa,Inc.,Düsseldorf,Germany(AerosilTM)、E.I.DuPont&Co.,Wilmington,DE和W.R.Grace&Co.,Columbia,MD(SyloidTM)在内的许多来源的非晶形粉末。胶态二氧化硅也称作胶体硅石、热解法二氧化硅、无水轻质硅酸、硅酐和烟化二氧化硅(silicon dioxide fumed)等。通过不同的生产工艺生产不同商品等级的胶态二氧化硅。这些改变不会影响二氧化硅含量、比重、折射率、颜色或晶形。然而,已知这些修改改变了胶态二氧化硅产品的颗粒大小、表面积和堆积密度。二氧化硅的平均颗粒大小一般小于或等于约15μm/堆积密度(小于或等于约21.0Ibs./ft3(336kg/m3))。优选二氧化硅是干粉形式且不是液体混悬液。
二氧化硅的含有量一般占剂型重量的约0.1-约2%、优选含量占剂型重量的约0.15-约1.0%(重量)且最优选含量占剂型重量的约0.25-约0.75%。
通式(I)化合物的制备方法描述在美国专利US 5,552,412中,将该文献引入本文作为参考,且外消旋混合物的拆分描述在WO97/16434中。可以使用活性组分本身或其药物上可接受的盐、溶剂合物和/或水合物的形式。术语"药物上可接受的盐"指的是来源于无机酸和有机酸的无毒性酸加成的盐。合适的盐衍生物包括卤化物、硫氰酸盐、硫酸盐、硫酸氢盐、亚硫酸盐、亚硫酸氢盐、芳基磺酸盐、烷基硫酸盐、膦酸盐、磷酸一氢盐、磷酸二氢盐、偏磷酸盐、焦磷酸盐、链烷酸盐、环烷基链烷酸盐、芳基链烷酸盐、己二酸盐、藻酸盐、天冬氨酸盐、苯甲酸盐、富马酸盐、葡庚糖酸盐、甘油磷酸盐、乳酸盐、马来酸盐、烟酸盐、草酸盐、棕榈酸盐、果胶酸盐、苦味酸盐、新戊酸盐、琥珀酸盐、酒石酸盐、柠檬酸盐、樟脑酸盐、樟脑磺酸盐、二葡糖酸盐、三氟乙酸盐等。通式(I)化合物的优选盐是酒石酸盐(特别是D-酒石酸盐)或柠檬酸盐。优选的化合物是拉索昔芬(顺式-6-苯基-5-[4-(2-吡咯烷-1-基乙氧基)苯基]-5,6,7,8-四氢萘-2-醇)。该活性组分在药物组合物中的一般含量小于或等于约10%w/w。就低剂量剂型应用而言,该活性组分在药物组合物中的一般含量低于4.0%w/w活性组分、更优选≥约0.01%w/w活性组分和<4%w/w活性组分,甚至更优选≥约0.01%w/w活性组分和≤约3.5%w/w活性组分,最优选≥约0.1%w/w活性组分和≤约2.5%w/w活性组分。
可以将药物组合物用于生产含有约0.05mg-约10.0活性组分/单位剂量、优选约0.1mg-约5.0mg活性组分/单位剂量的单位剂型。片剂大小(即单位剂型)一般为约100mg-600mg。本文所用的"低剂量剂型"指的是含有低于约5.0mg活性组分的单位剂量。一般的低剂量剂型含有约0.01-约5.0mg、优选约0.05mg-约4.0mg、更优选约0.1mg-约3.5mg、最优选约0.1mg-2.5mg活性组分。
例如,0.25mg、0.1mg和0.05mg片的片剂一般由含有约0.14%w/w活性组分的掺合物组成且片的大小可以改变以获得合适的剂量;而0.5mg片剂一般含有约0.68%w/w活性组分的掺合物。活性组分在最终药物组合物中的浓度一般通过增加或减少加入到该制剂中的稀释剂(例如乳糖)的量来调整。
一般通过在旋转压力机中压制来制备片剂。不过,对用于片剂形成的具体方法无限制且是本领域技术人员众所周知的。在片剂形成后,通常给片剂包一层或多层包衣层。可以给片剂包衣以掩盖气味,起密封层的作用和/或起刻印片剂表面徽标或商标的接受者的作用。常用的包衣层是糖包衣层(例如蔗糖或山梨醇包衣层)。另一方面,可以给片剂包成膜保护剂以改变片剂的溶出特性。例如,可以给片剂包衣防止预定时间期限内溶解的成膜包衣层,由此使活性组分延缓或延长释放。合适的成膜保护剂包括纤维素(例如羟丙基甲基纤维素、羟丙基纤维素、甲基纤维素)、聚乙烯吡咯烷酮和丙烯酸乙酯-甲基丙烯酸甲酯共聚物。包衣制剂还可以包括诸如加溶剂(例如三醋精)、防腐剂、增甜剂、调味剂、着色剂这样的添加剂和为药物提供优美外观的其它已知添加剂。还可以通过在制剂中使用大量诸如甘露糖醇这样味道良好的物质将所述的化合物配制成口嚼片。
另一方面,可以将活性药物掺合物填入胶囊。对具体的胶囊和用于填充胶囊的方法无限制且是药物生产领域的普通技术人员众所周知的。
可以按照各种方式包装药物组合物(或制剂)。一般来说,用于分发的制品包括在含有适宜形式的药物组合物的容器。合适的容器是本领域技术人员众所周知的且包括诸如瓶(塑料和玻璃)、小药囊、箔泡罩包等这样的材料。容器还可以包括防止不慎进入包装内含物的防填塞装置。此外,容器一般在其上带有说明容器内含物和任何适当警告或指示的标签。
含有本文所述的通式(I)化合物的药物组合物特别用于治疗或预防乳腺癌、骨质疏松、肥胖、心血管疾病、高胆固醇血症、子宫内膜异位症和前列腺疾病。因此,可以将含有通式(I)化合物的本文所述的药物制剂和方法用于生产上述治疗应用的药剂。可以将治疗有效量生产的药剂根据这类治疗或预防的需要对人给药。本文所用的术语"治疗有效量"指的是能够抑制或预防上述涉及的各种病理情况或其症状以及后遗症的活性组分的用量。术语"抑制"指的是阻止、治疗、减轻、改善、停止、遏制、缓解或逆转涉及所治疗相应疾病或由其导致的病理情况或症状发展或降低其严重程度。如果合适,可以照此将药物制剂用于医学治疗(急性或慢性)和/或预防(预防)性给药。剂量、给药频率和期限随诸如所治疗疾病的性质和严重程度、宿主的年龄和一般健康情况和宿主对活性组分的耐受性而改变。每日可以以单剂量给予药物组合物或药剂或在当天分多次剂量给药。该方案可以持续约2-3天或几周或几周以上。一般来说,将该组合物对人患者给药,每天1-4次,单位剂量为约0.05mg-约50mg,但上述剂量可以适当改变,这取决于患者的年龄、体重和医学情况以及给药类型。优选对人体患者的给药方案为每日给药约0.25mg/kg-约25mg/kg。
下列实施例解释通式(I)化合物的制备方法及其在本发明药物组合物和生产方法中的应用。尽管将特定的SERM化合物(拉索昔芬)用于解释本发明,但是本领域技术人员可以理解的是可以将本发明的方法用于得益于用本发明方法使药物组合物中活性组分效力和分布均匀性增加的任意化合物。这些实施例并不在任何方面用来限定本发明的范围且不应如此解释。
实施例
顺式-6-苯基-5-[4-(2-吡咯烷-1-基乙氧基)苯基]-5,6,7,8-四氢萘-2-
醇("拉索昔芬")的制备:
如美国专利US5,552,412所述制备拉索昔芬并再现如下。
在20℃和60psi(0.41MPa)下使1-[2-[4-(6-甲氧基-2-苯基-3,4-二氢萘-1-基)苯氧基]乙基]吡咯烷盐酸盐(盐酸萘福昔定(nafoxidenehydrochloride))(1.0g,2.16mmol)于20mL含有1.0g氢氧化钯/碳的无水乙醇中的溶液氢化19小时。过滤并蒸发而得到863mg(93%)的顺式-1-{2-[4-(6-甲氧基-2-苯基-1,2,3,4-四氢萘-1-基)苯氧基]乙基}吡咯烷。
1H-NMR(CDCl3.):δ3.50-3.80(m,3H),3.85(s,3H),4.20-4.40(m,3H),6.80-7.00(m,3H);MS 428(P+1)。
在0℃搅拌下向400mg(0.94mmol)的顺式-1-{2-[4-(6-甲氧基-2-苯基-1,2,3,4-四氢萘-1-基)苯氧基]乙基}吡咯烷于25mL二氯甲烷中的溶液中逐滴加入4.7ml(4.7mmol)1.0M三溴化硼的二氯甲烷溶液。在室温下3小时后,将该反应体系倾入100mL快速搅拌的饱和碳酸氢钠水溶液中。分离有机层、用硫酸钠干燥、过滤并浓缩至得到287mg(产率74%)的拉索昔芬、为游离碱。
1H-NMR(CDCl3):δ3.35(dd,1H),4.00(t,2H),4.21(d,1H),6.35(ABq,4H)。通过用过量4N HCl的二噁烷溶液处理该碱溶液、随后蒸发至干并用乙醚一起研制来制备相应的盐酸盐(MS:415[P+1])。
另一方面,可以使用下列方法制备拉索昔芬。
1-[2-[4-(6-甲氧基-2-苯基-3,4-二氢萘-1-基)苯氧基]乙基]吡咯烷的制备:将无水CeCl3(138g,560mmol)和THF(500mL)的混合物剧烈搅拌2小时。在独立的烧瓶中,将1-[2-(4-溴苯氧基)乙基]吡咯烷(100g,370mmol)的THF(1000mL)溶液冷却至-78℃并在20分钟内缓慢加入n-BuU(2.6M的己烷溶液,169mL,440mmol)。在15分钟后,将该溶液通过套管加入到在-78℃下冷却的CeCl3淤浆中并将该反应体系在-78℃下搅拌2小时。在-78℃下将6-甲氧基-1-四氢萘酮(65.2g,370mmol)的THF(1000mL)溶通过套管加入到芳基铈试剂中。将该反应体系缓慢温热至室温并总计搅拌16小时。将该混合物通过CeliteTM垫过滤。在真空中浓缩滤液并加入3N HCl(500mL)和Et2O(500mL)。在搅拌15分钟后,分离各层。用Et2O(2x)进一步洗涤水层。干燥(MgSO4)干燥合并的有机层、过滤并浓缩得到6-甲氧基-1-四氢萘酮(22g)。用5N NaOH将水层碱化至pH12并加入15%(NH4)2CO3水溶液(1000mL)。用CH2Cl2(2x)提取该含水混合物。干燥(MgSO4)有机溶液、过滤并浓缩得到棕色油状物。蒸馏出杂质(110℃-140℃,0.2mmHg)而得到产物(74g,57%)。
1HNMR(250MHz,CDCl3):δ7.27(d,J=8.7Hz,2H),6.92-6.99(m,3H),6.78(d,J=2.6Hz,1H),6.65(dd,J=8.6,2.6Hz,1H),5.92(t,J=4.7Hz,1H),4.15(t Hz,2H),3.80(s,3H),2.94(t,J=6.0Hz,2H),2.81(t,J=7.6Hz,2H),2.66(m,2H),2.37(m,2H),1.84(m,4H)。
1-[2-[4-(2-溴-6-甲氧基-3,4-二氢萘-1-基)苯氧基]乙基]吡咯烷的制备:向1-[2-[4-(6-甲氧基-3,4-二氢萘-1-基)苯氧基]乙基]吡咯烷(23g,72mmol)的THF(700mL)的溶液中分部分加入溴化吡啶鎓过溴化物(21.22g,60.55mmol)。将该反应体系搅拌60小时。通过Celite(塞利特硅藻土)垫借助于THF过滤沉淀。将黄白色固体溶于CH2Cl2和MeOH并将其从Celite中过滤出来。用0.5N HCl水溶液、随后用饱和NaHCO3(水溶液)洗涤该有机溶液。干燥(MgSO4)该有机溶液、过滤并浓缩至得到棕色固体(21.5g,83%)。
1HNMR(250MHz,CDCl3):δ7.14(d,J=8.7Hz,2H),6.97(d,J=8.8Hz,2H),6.71(d,J=2.2Hz,1H),6.55(m,2H),4.17(t,J=6.0Hz,2H),3.77(s,3H),2.96m,(4H),2.66(m,4H),1.85(m,4H)。
1-[2-[4-(6-甲氧基-2-苯基-3,4-二氢萘-1-基)苯氧基]乙基]吡咯烷盐酸盐(盐酸萘福昔定)的制备:向1-[2-[4-(2-溴-6-甲氧基-3,4-二氢萘-10-基)苯氧基]乙基]吡咯烷(19g,44mmol)、苯基硼酸(7.0g,57mmol)和四(三苯膦鎓)合钯(1.75g,1.51mmol)在THF(300mL)中的混合物中加入Na2CO3(13g,123mmol)的H2O(100mL)溶液。将该反应体系在回流状态下加热18小时。分离各层并用H2O、随后用盐水洗涤有机层。干燥(MgSO4)该有机溶液、过滤并浓缩至得到17.96g的棕色固体。将残余物溶于CH2Cl2与EtOAc的1∶1混合物(250mL)并加入1N HCl的Et2O溶液(100mL)。在搅拌2小时后,使产物从溶液中结晶并通过过滤收集到11g物质。浓缩母液至其体积的一半而又得到7.3g产物。
1-[2-[4-(6-甲氧基-2-苯基-1,2,3,4-四氢萘-1-基)苯氧基]乙基]吡咯烷的制备:将1-[2-[4-(6-甲氧基-2-苯基-3,4-二氢萘-1-基)苯氧基]乙基]吡咯烷盐酸盐(盐酸萘福昔定)(75g,162mmol)溶于1000mL的EtOH和300mL的MeOH。加入干燥的Pd(OH)2/碳并使该混合物在50℃和50psi(0.34MPa)下的帕尔振荡器上氢化68小时。用Celite过滤出催化剂并在真空中除去溶剂。将所得白色固体溶于CH2Cl2并用饱和NaHCO3(水溶液)洗涤该溶液。干燥(MgSO4)该有机溶液、过滤并浓缩至得到黄白色固体(62.6g,90%)。
顺式-6-苯基-5-[4-(2-吡咯烷-1-基乙氧基)苯基]-5,6,7,8-四氢萘-2-醇的制备:将顺式-1-[2-[4-(6-甲氧基-2-苯基-1,2,3,4-四氢萘-1-基)苯氧基]乙基]吡咯烷(12g,28mmol)、乙酸(75mL)和48%HBr(75mL)的混合物在100℃下加热15小时。将该溶液冷却并通过过滤收集所得白色沉淀。将该氢溴酸盐(9.6g,69%)溶于CHCl3/MeOH并与饱和NaHCO3(水溶液)一起搅拌。分离各层并用CHCl3/MeOH进一步提取水层。干燥(MgSO4)合并的有机层、过滤并浓缩至得到产物、为黄白色泡沫。
1HNMR(250MHz,CDCl3):δ7.04(m,3H),6.74(m,2H),6.63(d,J=8.3Hz,2H),6.50(m,3H),6.28(d,J=8.6Hz,2H),4.14(d,J=4.9Hz,1H),3.94(t,J=5.3Hz,2H),3.24(dd,J=12.5,4.1Hz,1H),2.95(m,4H),4H),2.14(m,1H),1.88(m,4H),1.68(m,1H)。
下列实施例将常规的成粒湿法和溶液湿成粒法与本发明(干成粒法)进行了比较。
实施例1
实施例1中所用的下列物质可以从下述相应的来源获得:
AvicelTMPH101(微晶纤维素) FMC Pharmaceutical(Philadelphia,
PA)
Lactose Fast FloTM 316 Foremost Corp.(Baraboo,WI)
硬脂酸镁 Mallinckrodt(St.Louis,MO)
羟丙基纤维素 Hercules Inc.(Hopewell,VA)
交联羧甲基纤维素钠 FMC Pharmaceutical(Philadelphia,
PA)
β-环糊精磺丁基醚 使用美国专利US6,153,746中所述的
方法制备
二氧化硅 Grace Davison(Columbia,MD)
ProSolvTM 50(硅化微晶纤维素) Penwest,Patterson,NJ
拉索昔芬常规湿成粒法(对比法)
按照所列顺序将下列组分加入到高剪切掺合机中。
乳糖 5.000g
微晶纤维素 17.432g
交联羧甲基纤维素钠 1.000g
羟丙基纤维素 1.250g
二氧化硅 0.125g
拉索昔芬 0.068g
将该混合物掺合约15分钟。在掺合的同时,在8.5分钟期限内加入适量水(约占干掺合物的63%w/w)且然后再持续掺合30秒至得到所需的湿团。随后将该湿团在真空(约50毫巴(mB))中干燥至水分低于约2%。通过安装有0.04英寸(0.10cm)筛和设定在1750rpm速度的圆边叶轮的圆锥形研磨机研磨干燥的颗粒。将该混合物在Turbula混合器上的150cc玻璃瓶中掺合约10分钟。向该混合物中加入硬脂酸镁(0.125g)且然后掺合约5分钟。然后使用KilianTMT100压片机(购自Kilian&Co.,Inc.,Horsham,PA)将该活性掺合物压制成片剂。
拉索昔芬药物的溶液湿成粒法(对比法)
向安装了混合器的250mL玻璃烧杯中加入水(100mL)。在搅拌的同时,加入β-环糊精磺丁基醚(0.452g),随后加入拉索昔芬(0.113g)并搅拌至β-环糊精磺丁基醚和拉索昔芬溶解且形成溶液。然后按照所列顺序将下列组分加入到高剪切掺合机中。
乳糖 5.000g
硅化微晶纤维素 17.540g
交联羧甲基纤维素钠 1.000g
羟丙基纤维素 1.250g
将该混合物掺合约2分钟。在掺合的同时,在3分钟期限内加入拉索昔芬:水溶液。随后将湿团在50℃和强制热空气烘箱中干燥至水分低于约1%。使干燥的颗粒通过安装有0.005英寸(0.14cm)筛和设定在1750rpm速度的圆边叶轮的圆锥形研磨机。向该混合物中加入硬脂酸镁(0.125g)且然后掺合约5分钟。然后使用ManestyTM F-压片机(购自Thomas Engineering Inc.,Hoffman Estates,IL)将该活性掺合物压制成片剂。
拉索昔芬干成粒法
按照所列顺序将下列组分加入到高剪切掺合机中。
乳糖 1052.25g
微晶纤维素 375.00g
交联羧甲基纤维素钠 45.00g
二氧化硅 7.50g
拉索昔芬 5.25g
将乳糖、微晶纤维素、交联羧甲基纤维素钠和二氧化硅掺合5分钟。接下来加入拉索昔芬并掺合约15分钟。然后从该剪切掺合机中放出活性掺合物并在双壳"V"型掺合机中掺合约5分钟。向该活性掺合物中加入硬脂酸镁(7.50g)并掺合约5分钟。在Vector FreundTM滚筒式压制装置中对活性掺合物进行辊压并通过安装了0.033"(0.084cm)筛的旋转成粒机(均购自Vector Corp.,Marion,IA)研磨。将该活性颗粒在双壳"V"型掺合机中掺合约5分钟。向该颗粒中再加入部分硬脂酸镁(7.50g)并掺合约5分钟。将最终的掺合物在KilianTM T100旋转压片机上压制成片剂。
下表1概括了对三种不同方法使用高效液相色谱法得到的稳定性结果。
表1
拉索昔芬稳定性比较 | |||
生产方法 | 干法成粒 | 常规的湿法成粒(对比) | 药物的溶液湿法成粒(对比) |
加入的药物百分比 | 0.14 | 0.28 | 0.068 |
最初的杂质总百分比 | 0.02 | 未得到 | 0.95 |
5℃下杂质总百分比 | 12个月时为0.13 | 6周时为0.54 | 6周时为1.43 |
30℃下杂质总百分比 | 12个月时为0.13 | 6周时为1.21 | 6周时为2.03 |
40℃/75%RH下的杂质总百分比 | 6个月时为0.41 | 6周时为4.3 | 6周时为3.10 |
50℃下的杂质总百分比 | 6个月时为0.39 | 6周时为5.26 | 6周时为4.25 |
Claims (14)
1.具有均匀药物分布和效力的药物组合物的制备方法,该方法包括下列顺序的步骤:
(1)在高剪切成粒机中将二氧化硅和至少一种药物上可接受的赋形剂、载体或稀释剂掺合适当的时间以产生掺合的混合物;
(2)向成粒机中加入活性组分且再掺合一定时间期限而形成活性掺合物;
(3)将该活性掺合物从成粒机中转入掺合机中;
(4)任选向所述的活性掺合物中加入一种或多种其它药物上可接受的赋形剂、载体或稀释剂;和
(5)掺合适当时间期限以形成具有均匀活性组分分布和均匀效力的药物组合物。
2.具有均匀药物分布和效力的药物组合物的制备方法,该方法包括下列顺序的步骤:
(1)在高剪切成粒机中将二氧化硅和至少一种药物上可接受的赋形剂、载体或稀释剂掺合约5分钟以产生掺合的混合物;
(2)向成粒机中加入活性组分并掺合约10-约15分钟而形成活性掺合物;
(3)将该活性掺合物从成粒机中转入掺合机中;
(4)向所述的活性掺合物中任选加入一种或多种其它药物上可接受的赋形剂、载体或稀释剂;和
(5)掺合约5-约15分钟以形成具有均匀活性组分分布和均匀效力的药物组合物。
3.权利要求1或2的方法,其中所述的活性组分是选择性雌激素受体调节剂。
5.权利要求3所述的方法,其中所述的选择性雌激素受体调节剂选自下列化合物组成的组:顺式-6-(4-氟-苯基)-5-[4-(2-哌啶-1-基-乙氧基)-苯基]-5,6,7,8-四氢-萘-2-醇;(-)-顺式-6-苯基-5-[4-(2-吡咯烷-1-基-乙氧基)-苯基]-5,6,7,8-四氢-萘-2-醇;顺式-6-苯基-5-[4-(2-吡咯烷-1-基-乙氧基)-苯基]-5,6,7,8-四氢萘-2-醇;顺式-1-[6′-吡咯烷乙氧基-3′-吡啶基]-2-苯基-6-羟基-1,2,3,4-四氢萘-1-(4′-吡咯烷乙氧基苯基)-2-(4″-氟苯基)-6-羟基-1,2,3,4-四氢异喹啉;顺式-6-(4-羟基苯基)-5-[4-(2-哌啶-1-基-乙氧基)-苯基]-5,6,7,8-四氢萘-2-醇;和1-(4′-吡咯烷乙氧基苯基)-2-苯基-6-羟基-1,2,3,4-四氢异喹啉;其前体药物;或所述化合物或所述前体药物的药物上可接受的盐、水合物或溶剂合物。
6.权利要求5所述的方法,其中所述的选择性雌激素受体调节剂是顺式-6-苯基-5-[4-(2-吡咯烷-1-基乙氧基)苯基]-5,6,7,8-四氢萘-2-醇;其前体药物;或所述选择性雌激素受体调节剂或所述前体药物的药物上可接受的盐、水合物或溶剂合物。
7.权利要求6所述的方法,其中所述的选择性雌激素受体调节剂是顺式-6-苯基-5-[4-(2-吡咯烷-1-基乙氧基)苯基]-5,6,7,8-四氢萘-2-醇的D-酒石酸盐。
8.上述权利要求中任意一项所述的方法,进一步包括将所述药物组合物加工成单位剂型的步骤。
9.上述权利要求中任意一项所述的方法,其中所述的活性组分在所述单位剂型中的含量约0.01-约10.0mg。
10.上述权利要求中任意一项所述的方法,其中所述的活性组分在所述单位剂型中的含量约0.1-约3.5mg。
11.上述权利要求中任意一项所述的方法,其中所述的二氧化硅的含量占所述单位剂型重量的约0.1-约2%。
12.低剂量药物组合物,包括活性组分、二氧化硅和至少一种药物上可接受的赋形剂、载体或稀释剂,其中所述活性组分的含有量低于4.0%w/w活性组分且所述的二氧化硅的含有量约0.1-约2重量%。
13.药物组合物,包括顺式-6-苯基-5-[4-(2-吡咯烷-1-基乙氧基)苯基]-5,6,7,8-四氢萘-2-醇的D-酒石酸盐、二氧化硅和至少一种药物上可接受的赋形剂、载体或稀释剂,其中所述顺式-6-苯基-5-[4-(2-吡咯烷-1-基乙氧基)苯基]-5,6,7,8-四氢萘-2-醇的D-酒石酸盐的含有量小于或等于约10.0%w/w且所述的二氧化硅的含有量约0.1-约2重量%。
14.低剂量药物组合物,包括顺式-6-苯基-5-[4-(2-吡咯烷-1-基乙氧基)苯基]-5,6,7,8-四氢萘-2-醇的D-酒石酸盐、二氧化硅和至少一种药物上可接受的赋形剂、载体或稀释剂,其中所述顺式-6-苯基-5-[4-(2-吡咯烷-1-基乙氧基)苯基]-5,6,7,8-四氢萘-2-醇的D-酒石酸盐的含有量低于约4.0%w/w且所述的二氧化硅的含有量约0.1-约2重量%。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28784101P | 2001-05-01 | 2001-05-01 | |
US60/287,841 | 2001-05-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1531423A true CN1531423A (zh) | 2004-09-22 |
CN1240375C CN1240375C (zh) | 2006-02-08 |
Family
ID=23104578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028092554A Expired - Fee Related CN1240375C (zh) | 2001-05-01 | 2002-03-13 | 具有均匀药物分布和效力的低剂量药物组合物的制备方法 |
Country Status (44)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106176649A (zh) * | 2016-08-31 | 2016-12-07 | 北京斯利安药业有限公司 | 叶酸vb12片及其制备方法 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1487790B1 (en) | 2002-03-28 | 2010-03-03 | Pfizer Products Inc. | Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization |
PA8576201A1 (es) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
US7444197B2 (en) | 2004-05-06 | 2008-10-28 | Smp Logic Systems Llc | Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes |
US7799273B2 (en) | 2004-05-06 | 2010-09-21 | Smp Logic Systems Llc | Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes |
CA2652657A1 (en) * | 2006-05-17 | 2008-11-27 | Wm. Wrigley Jr. Company | Method of preparing a food product |
US8951562B2 (en) * | 2006-11-10 | 2015-02-10 | Atacama Labs Oy | Method and apparatus or dry granulation |
FI20080351A0 (fi) * | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi |
FI20070521L (fi) | 2006-11-10 | 2008-05-11 | Atacama Labs Oy | Rakeita, tabletteja ja rakeistusmenetelmä |
CA2671727C (en) * | 2006-12-20 | 2016-02-16 | Genpharm Ulc | A composition containing a bisphosphonic acid in combination with vitamin d |
US20080181972A1 (en) * | 2007-01-29 | 2008-07-31 | Valentina Amico | Compositions and Methods for Maintaining, Strengthening, Improving, or Promoting Eye Health |
LT2487166T (lt) | 2007-02-23 | 2016-11-10 | Gilead Sciences, Inc. | Terapinių agentų farmakokinetinių savybių moduliatoriai |
SG190618A1 (en) | 2008-05-02 | 2013-06-28 | Gilead Sciences Inc | The use of solid carrier particles to improve the processability of a pharmaceutical agent |
CA2723409C (en) * | 2008-05-09 | 2016-11-08 | Atacama Labs Oy | Method and apparatus for dry granulation |
US20170065529A1 (en) | 2015-09-09 | 2017-03-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical dosage form for immediate release of an indolinone derivative |
RS57142B1 (sr) | 2008-06-06 | 2018-07-31 | Boehringer Ingelheim Int | Farmaceutski dozni oblik u vidu kapsule koji sadrži formulaciju suspenzije indolinon derivata |
WO2010094535A1 (en) * | 2009-01-29 | 2010-08-26 | Ucb Pharma, S.A. | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
ES2520990T3 (es) * | 2009-01-29 | 2014-11-12 | Ucb Pharma, S.A. | Composiciones farmacéuticas que comprenden derivados de 2-oxo-1-pirrolidina |
US20140350945A1 (en) * | 2013-05-22 | 2014-11-27 | Professional Compounding Centers Of America | System and Method for Validation of Pharmaceutical Composition Formulations |
CN103830196A (zh) * | 2014-03-14 | 2014-06-04 | 王志刚 | 一种酒石酸拉索昔芬分散片及其制备方法 |
BR112019015904A2 (pt) * | 2017-02-17 | 2020-03-24 | Massachusetts Institute Of Technology | Sistemas e métodos para a fabricação de comprimidos, incluindo comprimidos farmacêuticos |
CZ309820B6 (cs) * | 2021-04-23 | 2023-11-08 | Pro.Med.Cs Praha A.S. | Způsob přípravy pevné lékové formy obsahující kompozici s nízkým obsahem účinné látky |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3725555A (en) * | 1967-08-01 | 1973-04-03 | Ciba Geigy Corp | Bactericidal compositions and method of killing bacteria using bis-(phenoxyphenyl) carbonates |
US3725556A (en) * | 1970-11-12 | 1973-04-03 | D Hanssen | Method of manufacturing rapidly disintegrating pharmaceutical tablets |
US4013785A (en) * | 1975-03-21 | 1977-03-22 | Bristol-Myers Company | Apap tablet containing fumed silica and process for manufacturing same |
GB1570993A (en) * | 1976-05-21 | 1980-07-09 | Fisons Ltd | Pharmaceutical tablet formulation |
DE2845326C2 (de) * | 1978-10-18 | 1985-05-23 | Beiersdorf Ag, 2000 Hamburg | Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung |
US4489026A (en) * | 1982-09-07 | 1984-12-18 | The Upjohn Company | Process for preparing solid unit dosage forms of ultra-low dose drugs |
US5004613A (en) * | 1987-07-27 | 1991-04-02 | Mcneil-Ppc, Inc. | Oral sustained release pharmaceutical formulation and process |
US5047246A (en) * | 1988-09-09 | 1991-09-10 | Bristol-Myers Company | Direct compression cyclophosphamide tablet |
US5107331A (en) * | 1989-03-07 | 1992-04-21 | The Color Group | Method and apparatus for producing half-tone separations at the same screen angle |
US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
IE67345B1 (en) * | 1991-03-12 | 1996-03-20 | Akzo Nv | Low dose dry pharmaceutical preparations |
US5464632C1 (en) * | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
US5358941A (en) * | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
US5928668A (en) * | 1993-12-21 | 1999-07-27 | Applied Analytical Industries, Inc. | Method for dry blend compression of medicaments |
US5976570A (en) * | 1993-12-21 | 1999-11-02 | Applied Analytical Industries, Inc. | Method for preparing low dose pharmaceutical products |
ES2082723B1 (es) * | 1994-07-20 | 1996-10-01 | Lilly Sa | Formulacion farmaceutica de fluoxetina en forma dispersable. |
US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
ES2079327B1 (es) * | 1994-12-13 | 1996-08-01 | Lilly Sa | Formulaciones farmaceuticas de cefaclor. |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
GB9501127D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
US5726168A (en) * | 1995-10-12 | 1998-03-10 | Eli Lilly And Company | Lipophilic benzothiophenes |
UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
US5733578A (en) * | 1995-11-15 | 1998-03-31 | Edward Mendell Co., Inc. | Directly compressible high load acetaminophen formulations |
IL120266A (en) * | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
US5916916A (en) * | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
JPH10204082A (ja) * | 1996-10-25 | 1998-08-04 | Eli Lilly & Co | 選択的エストロゲンレセプターモジュレーターとしての活性を有する置換されたベンゾ[b]チオフェン化合物 |
US6080427A (en) * | 1997-04-17 | 2000-06-27 | Bristol-Myers Squibb Company | Cefadroxil monohydrate tablet formulation |
PT889056E (pt) * | 1997-07-01 | 2006-07-31 | Pfizer Prod Inc | Processo para produzir um,a ciclodextrina. |
US6300367B1 (en) * | 1999-04-20 | 2001-10-09 | Protein Technologies International, Inc. | Composition for and method of preventing or treating breast cancer |
US6555551B1 (en) * | 1999-08-31 | 2003-04-29 | Mutual Pharmaceutical Co., Inc. | Stable formulations of ACE inhibitors, and methods for preparation thereof |
AR029538A1 (es) * | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
-
2002
- 2002-03-13 OA OA1200300274A patent/OA12596A/en unknown
- 2002-03-13 YU YUP-815/03A patent/YU81503A/sh unknown
- 2002-03-13 EP EP02702671A patent/EP1383482B1/en not_active Expired - Lifetime
- 2002-03-13 KR KR1020037014223A patent/KR100568380B1/ko not_active IP Right Cessation
- 2002-03-13 EE EEP200300537A patent/EE200300537A/xx unknown
- 2002-03-13 UA UA2003109816A patent/UA75135C2/uk unknown
- 2002-03-13 ES ES02702671T patent/ES2286226T3/es not_active Expired - Lifetime
- 2002-03-13 MX MXPA03009391A patent/MXPA03009391A/es active IP Right Grant
- 2002-03-13 AP APAP/P/2003/002900A patent/AP2003002900A0/en unknown
- 2002-03-13 CZ CZ20032959A patent/CZ20032959A3/cs unknown
- 2002-03-13 DE DE60221238T patent/DE60221238T2/de not_active Expired - Fee Related
- 2002-03-13 JP JP2002584892A patent/JP2004531537A/ja not_active Ceased
- 2002-03-13 NZ NZ528886A patent/NZ528886A/en unknown
- 2002-03-13 DK DK02702671T patent/DK1383482T3/da active
- 2002-03-13 CA CA002445519A patent/CA2445519C/en not_active Expired - Fee Related
- 2002-03-13 AT AT02702671T patent/ATE367152T1/de not_active IP Right Cessation
- 2002-03-13 PT PT02702671T patent/PT1383482E/pt unknown
- 2002-03-13 IL IL15839002A patent/IL158390A0/xx unknown
- 2002-03-13 AU AU2002236166A patent/AU2002236166B2/en not_active Ceased
- 2002-03-13 EA EA200301040A patent/EA005949B1/ru not_active IP Right Cessation
- 2002-03-13 GE GE5339A patent/GEP20053654B/en unknown
- 2002-03-13 BR BR0209283-2A patent/BR0209283A/pt not_active IP Right Cessation
- 2002-03-13 CN CNB028092554A patent/CN1240375C/zh not_active Expired - Fee Related
- 2002-03-13 PL PL02366453A patent/PL366453A1/xx not_active Application Discontinuation
- 2002-03-13 SK SK1355-2003A patent/SK286536B6/sk not_active IP Right Cessation
- 2002-03-13 HU HU0401391A patent/HUP0401391A3/hu unknown
- 2002-03-13 WO PCT/IB2002/000766 patent/WO2002087546A2/en active Application Filing
- 2002-04-23 US US10/131,556 patent/US7037530B2/en not_active Expired - Fee Related
- 2002-04-25 TW TW091108572A patent/TWI264311B/zh not_active IP Right Cessation
- 2002-04-26 DO DO2002000389A patent/DOP2002000389A/es unknown
- 2002-04-29 AR ARP020101574A patent/AR033288A1/es unknown
- 2002-04-29 GT GT200200078A patent/GT200200078A/es unknown
- 2002-04-29 PA PA20028544401A patent/PA8544401A1/es unknown
- 2002-04-30 PE PE2002000368A patent/PE20021137A1/es not_active Application Discontinuation
- 2002-04-30 UY UY27277A patent/UY27277A1/es not_active Application Discontinuation
-
2003
- 2003-07-08 TN TNPCT/IB2002/000766A patent/TNSN03106A1/fr unknown
- 2003-10-07 ZA ZA200307819A patent/ZA200307819B/en unknown
- 2003-10-09 IS IS6985A patent/IS6985A/is unknown
- 2003-10-21 HR HR20030858A patent/HRP20030858A2/xx not_active Application Discontinuation
- 2003-10-21 NO NO20034709A patent/NO20034709L/no not_active Application Discontinuation
- 2003-10-28 BG BG108297A patent/BG108297A/bg unknown
- 2003-10-28 MA MA27375A patent/MA27017A1/fr unknown
- 2003-10-31 EC EC2003004826A patent/ECSP034826A/es unknown
-
2004
- 2004-10-30 HK HK04108533A patent/HK1065705A1/xx not_active IP Right Cessation
-
2005
- 2005-12-13 US US11/302,894 patent/US7176221B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106176649A (zh) * | 2016-08-31 | 2016-12-07 | 北京斯利安药业有限公司 | 叶酸vb12片及其制备方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1240375C (zh) | 具有均匀药物分布和效力的低剂量药物组合物的制备方法 | |
CN100344278C (zh) | 拉索昔芬片剂及其包衣层 | |
AU2002236166A1 (en) | Method for manufacturing a low dose pharmaceutical composition | |
CN1251990A (zh) | 含有阿莫西林和克拉维酸盐的药物制剂 | |
CN1487827A (zh) | 不吸湿性丙戊酸钠组合物的制备方法 | |
CN1903182A (zh) | 小型化盐酸沙格雷酯经口给药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1065705 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060208 |